Jan 31, 2025 · The United States Food and Drug Administration (FDA) has licensed two single-antigen hepatitis A vaccines (Havrix and Vaqta) and one combination vaccine for protection against both hepatitis A and hepatitis B (Twinrix) for use in the US.

Oct 30, 2023 · HAVRIX is indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older.

Jun 12, 2024 · Havrix vaccine is used to help prevent this disease in adults. Havrix works by exposing you to a small amount of the virus, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.

HAVRIX is indicated for active immunization against disease caused by hepatitis A virus (HAV). HAVRIX is approved for use in persons 12 months of age and older.

HAVRIX is a sterile suspension containing formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain) adsorbed onto aluminium hydroxide. The virus is propagated in MRC

Jan 31, 2025 · HAVRIX® VAQTA® TWINRIX® Talk to your doctor to determine which vaccine is right for you.

Consult package inserts for vaccine storage and handling guidance: (Havrix, Twinrix, VAQTA, and more package inserts…) Includes proper storage and handing details, shelf life, reconstitution instructions… Recommendations. Current ACIP Recommendations; References and Resources on Hepatitis A. Hepatitis A Resources and Links

Jan 8, 2025 · Havrix Vaccine package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

Dec 18, 2024 · HAVRIX (Hepatitis A Vaccine) is a sterile suspension of inactivated virus for intramuscular administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. After removal of the cell culture medium, the cells are lysed to form a suspension.

Sep 16, 2024 · HAVRIX is indicated for active immunization against disease caused by hepatitis A virus . HAVRIX is approved for use in persons 12 months of age and older. Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV. Dosage for Havrix Preparation For Administration. Shake well before use.